Abivax SA (ABVX) financial statements
Abivax SA reported revenue of 5M EUR in fiscal 2025, down 21.4% a year over 4 years.
Net income was -336M EUR and the operating margin -5384.2%, against -346.1% in 2021.
Free cash flow was -161M EUR.
The diluted share count rose 350% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions (EUR).
Income statement
Fiscal years, in EUR, from Abivax SA's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 12M EUR | 5M EUR | 5M EUR | 12M EUR | 5M EUR |
| Research and development | 48M EUR | 48M EUR | 103M EUR | 147M EUR | 178M EUR |
| Selling, general and admin | 6M EUR | 7M EUR | 22M EUR | 33M EUR | 68M EUR |
| Operating income | -41M EUR | -65M EUR | -127M EUR | -173M EUR | -246M EUR |
| Interest expense | 4M EUR | 7M EUR | 28M EUR | 17M EUR | 112M EUR |
| Pre-tax income | -42M EUR | -61M EUR | -148M EUR | -176M EUR | -330M EUR |
| Income tax | 0 EUR | 0 EUR | 0 EUR | 0 EUR | 6M EUR |
| Net income | -42M EUR | -61M EUR | -148M EUR | -176M EUR | -336M EUR |
| EPS (diluted) | -2.75 EUR | -3.18 EUR | -3.43 EUR | -2.80 EUR | -4.83 EUR |
| Diluted shares | 15M | 19M | 43M | 63M | 70M |
| Operating margin | -346.1% | -1414.7% | -2756.5% | -1389.5% | -5384.2% |
| Net margin | -354.9% | -1325.3% | -3197.1% | -1415.7% | -7354.5% |
Balance sheet
Fiscal years, in EUR, from Abivax SA's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and short-term investments | 61M EUR | 27M EUR | 252M EUR | 144M EUR | 517M EUR |
| Total current assets | 75M EUR | 36M EUR | 286M EUR | 171M EUR | 551M EUR |
| Property, plant and equipment | 305,000 EUR | 2M EUR | 878,000 EUR | 3M EUR | 2M EUR |
| Goodwill | 32M EUR | 18M EUR | 18M EUR | 18M EUR | 18M EUR |
| Total assets | 109M EUR | 76M EUR | 327M EUR | 205M EUR | 584M EUR |
| Total current liabilities | 32M EUR | 51M EUR | 91M EUR | 94M EUR | 63M EUR |
| Total liabilities | 83M EUR | 68M EUR | 131M EUR | 165M EUR | 129M EUR |
| Shareholders' equity | 26M EUR | 7M EUR | 196M EUR | 41M EUR | 455M EUR |
| Net debt | -61M EUR | -27M EUR | -252M EUR | -144M EUR | -517M EUR |
Cash flow
Fiscal years, in EUR, from Abivax SA's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | -45M EUR | -54M EUR | -97M EUR | -154M EUR | -161M EUR |
| Capital spending | 47,000 EUR | 323,000 EUR | 265,000 EUR | 643,000 EUR | 142,000 EUR |
| Free cash flow | -45M EUR | -54M EUR | -97M EUR | -155M EUR | -161M EUR |
| Stock-based compensation | 828,000 EUR | -1M EUR | 8M EUR | 20M EUR | 35M EUR |
| Free cash flow margin | -377.0% | -1183.9% | -2107.7% | -1242.8% | -3528.9% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ABVX.
Open ABVX in InvestinglyQuestions
What was Abivax SA's revenue in 2025?
5M EUR in fiscal 2025, from its 10-K filing.
How much free cash flow does Abivax SA generate?
-161M EUR in fiscal 2025 (operating cash flow minus capital spending).
From Abivax SA's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.